Mabex syrups in dose 5yrs old patient
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
"Mabex" is the brand name for mebendazole, an anthelmintic (deworming) drug available as a syrup/suspension formulation commonly used in children.
Mabex (Mebendazole) — Dosing in a 5-Year-Old Child
Standard Pediatric Dosing
Mebendazole is safe for use in children ≥2 years of age. The dose is the same for adults and children >2 years — no weight-based adjustment is needed for intestinal helminth infections.
| Infection | Dose | Duration |
|---|---|---|
| Pinworm (Enterobius vermicularis) | 100 mg once | Single dose; repeat after 2 weeks |
| Roundworm (Ascaris lumbricoides) | 100 mg twice daily (morning + evening) | 3 consecutive days |
| Whipworm (Trichuris trichiura) | 100 mg twice daily | 3 consecutive days |
| Hookworm (Necator americanus, Ancylostoma duodenale) | 100 mg twice daily | 3 consecutive days |
| Mixed infections / mass treatment | 500 mg single dose | Once |
For a 5-year-old, the syrup formulation is preferable. Each dose = 100 mg regardless of weight, as the dosing schedule is identical for all children >2 years.
Mechanism of Action
Mebendazole binds to parasite β-tubulin, blocking microtubule polymerization. This inhibits glucose uptake, depletes glycogen stores, and leads to parasite death and expulsion in feces.
Important Points for a 5-Year-Old
- Minimum age: Safe for children ≥2 years. Rare risk of convulsions reported in infants <1 year.
- No weight-based dosing needed — flat 100 mg dose applies.
- Syrup/chewable: A chewable/suspension formulation exists specifically for pediatric use to improve palatability and compliance.
- Reinfection is common: Treat all household contacts for pinworm; repeat dose at 2 weeks is essential.
- Contraindicated in pregnancy — not relevant here but important for the caregiver.
- Adverse effects: Generally mild — abdominal pain, diarrhea, nausea; usually transient.
- Avoid combination with metronidazole — increases risk of Stevens–Johnson syndrome/toxic epidermal necrolysis.
— Goodman & Gilman's The Pharmacological Basis of Therapeutics | Lippincott Illustrated Reviews: Pharmacology | Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.